Enveda raises $311 million Series E to advance AI-discovered natural drugs into trials
The biotech startup secured a $311 million round at a $2 billion valuation to move plant- and microbe-derived AI drug candidates into human studies.
Enveda, a biotechnology company that applies artificial intelligence to uncover therapeutic compounds from plants and microbes, announced a $311 million Series E financing round that values the firm at $2 billion. The round was led by Catalio Capital Management with participation from Iconiq and other investors, and it doubles the valuation the company reported a year earlier. The capital infusion is earmarked for expanding the company’s pipeline of AI-identified drug candidates and moving them further into clinical development.
Founded in 2019 by Viswa Colluru, an early employee of Recursion Pharmaceuticals, Enveda was built on the premise that nature’s chemical diversity can be accessed more efficiently through AI-driven discovery. Rather than synthesizing molecules from scratch, the company’s platform screens vast libraries of natural products to pinpoint those with therapeutic potential. While artificial intelligence has yet to deliver an FDA-approved drug, Enveda is among a growing cohort of firms that are transitioning AI-generated leads into human trials.
The startup currently has several candidates under investigation in patients. One program targets severe skin conditions, leveraging a natural compound identified by the AI platform. Another candidate is designed to help patients maintain weight loss after discontinuing GLP-1-based therapies, a growing need as the market for obesity treatments expands. Both programs represent early-stage validation of Enveda’s approach to translating nature-derived molecules into clinical candidates.
Enveda’s latest financing reflects broader investor confidence in the convergence of AI and biopharma. The company’s valuation increase signals that capital markets see tangible progress in moving AI-discovered molecules beyond the discovery phase. For founders, the round underscores the importance of pairing sophisticated computational tools with deep domain expertise in natural product chemistry. For operators, the infusion provides resources to scale laboratory validation, regulatory preparation, and trial execution. Investors gain exposure to a differentiated pipeline that could address therapeutic areas where conventional chemistry has struggled.
Looking ahead, Enveda will need to demonstrate that its AI-identified compounds can meet the safety and efficacy thresholds required for regulatory approval. Success in the ongoing skin-condition and weight-maintenance studies could pave the way for additional indications and attract further partnership opportunities. The company’s ability to translate its computational predictions into marketable medicines will be a key metric for stakeholders as the AI-driven drug discovery sector matures.